Interview released with UCB: Immunogenicity innovations in 2016
SMi’s 3rd annual Immunogenicity conference will be running at Holiday Inn Kensington Forum, London, UK on 13-14 June 2016.
"The greatest challenge within immunogenicity is to understand and execute the translational experiments needed to demonstrate efficacy."
LONDON, UNITED KINGDOM, April 7, 2016 /EINPresswire.com/ -- Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time to engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!— Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
In the run up to the event, SMi Group have caught up with the chair of day 2 Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB to find out his opinion on the recent challenges and developments in the immunogenicity field.
SMi: Which area of immunogenicity is demonstrating the most developments?
A.K.: “The obvious area is within immuno-oncology with the determination of immunogenic epitopes that can be targeted for treatment. However, the progress made in other indications with clinical data now coming through in allergic disease and diabetes suggests that immunogenicity, as a concept, has massive implications on future therapies”.
The full interview is available for download at www.immuno.co.uk/ein
This year’s event will feature exclusive case studies from the industry leaders such as: Selecta Biosciences, MHRA, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, ISA Pharmaceuticals, Baxalta, EpiVax, Janssen, Abzena, ProImmune, and many more.
Key Sessions:
• MHRA: Towards harmonisation of immunogenicity assays
• Integration of immunogenicity risk data to forecast clinical outcomes
• A harmonised approach to interpretation and reporting of clinical immunogenicity data
• Development and validation of cell based antibody neutralisation assays
There will be two interactive post-conference workshops running alongside the conference. The first workshop entitled ‘Approaches to standardising assays for measuring drug levels and anti-drug antibodies to biotherapeutics in clinical practice’ will be led by Hishani Kirby Associates and GlaxoSmithKline. The second workshop ‘Unwanted immunogenicity from bench to bedside’ will be led by IPM Biotech and ImmunXperts.
For further information or to register please visit the event website www.immuno.co.uk/ein or contact
Matthew Apps on +44 (0) 207 827 6093 or mapps@smi-online.co.uk
For sponsorship enquiries, contact Alia Malick on +44 (0) 207 827 6168 or amalick@smi-online.co.uk
3rd annual Immunogenicity conference
13-14 June 2016
Holiday Inn Kensington Forum, London, UK
www.immuno.co.uk/ein
#immunosmi
---- END ----
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Anna Serazetdinova
SMi Group Ltd
+44702078276180
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
